Illustration: Natalie Peeples/Axios
Synaptrix raised a $10 million Series A to continue development of its drug-free device for postoperative pain, CEO Shyamy Sastry tells Axios exclusively.
Why it matters: Patients receiving an opioid prescription after short-stay surgeries have a 44% increased risk of long-term opioid use.
